Albany, NY -- (SBWIRE) -- 07/19/2017 -- Oligonucleotides have a comprehensive range of applications in areas such as molecular biology, biotechnology, and diagnosis. They are widely used in life science as PCR and microarray-based reagents; probe and primer reagents in DNA-based diagnostics test kits; and therapeutic agents to treat a wide range of diseases such as cancer, Alzheimer's disease, Parkinson's disease, and muscle dystrophy. For therapeutics use, oligonucleotides come in various forms such as antisense oligonucleotides, nucleic acid aptamers, and RNAi therapeutics such as small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), and anti-micro RNAs (anti-miRs). Only few FDA approved oligonucleotide therapeutic drugs are available in the market, but more than 100 are still in different stages of pipeline and in preclinical development. The rising applications of oligonucleotides in therapeutics and diagnostics applications is expected to boost the growth of segment over the forecast period.

The global Oligonucleotide Synthesis Market was valued at US$ 1,650.0 Mn in 2016 and is estimated to reach US$ 4,189.9 Mn by 2025 at a CAGR of 11.2% from 2017 to 2025.

Inquire for a Sample Copy of Report - http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=11804

The global Oligonucleotide synthesis market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global oligonucleotide synthesis market in 2016 in terms of value, and is expected to continue the dominance during the forecast period. Rising number of pharmaceutical companies focusing on applications of oligonucleotides in therapeutics, research and diagnostics is expected to drive the growth of market in North America. Moreover, rising incidences of genetic disease in the region, develops high demand for researchers to devlop newer and advanced drugs to treat such disease is expected to propel the growth of oligonucleotide synthesis market over forecast period.

Biopharmaceutical companies and research institutes are targeting treatment of rare diseases such as spinal muscular atrophy (SMA), Duchene muscular dystrophy (DND), and other chronic diseases such as cancer and DNA/RNA oligonucleotides are playing an essential part of the research activities involving genomic and transcriptomic studies of the diseases.

Europe accounted for the second largest share of the global oligonucleotide synthesis market in terms of value. Increase in development of newer and sophisticated technologies for developing new molecules of oligonucleotides for therapeutic use are expected to drive the growth of the Europe oligonucleotide synthesis market. Start-up companies with new technologies and rich patent portfolios are aiming to advance new classes of oligo therapeutics. For instance, Silence Therapeutics, a U.K.-based company, is focusing on developing siRNA technology and delivery systems into successful commercial drug products by targeting single mRNA in the cell. Moderna Therapeutics, a company based in Cambridge, Massachusetts, is not a traditional oligonucleotide company; however, its mRNA platform is developed to deliver multiple novel clinical candidates. The company is aiming to innovate and deliver the next generation of oligonucleotide therapeutics. Germany is expected to register high growth in terms of CAGR in oligonucleotide synthesis market. Increasing government supports for research and development activities of healthcare sector is expected to drive the growth of the U.K. market.

Asia Pacific is expected to register highest CAGR among the regions in the global oligonucleotide synthesis market during the forecast period of 2017-2025. China is expected to register high growth in terms of CAGR owing to presence of high number of small companies provides reagents, and consumables for oligonucleotide synthesis. Developing countries such as Japan, and India offer lucrative growth prospects in the oligonucleotide synthesis market due to factors such as improving health care infrastructure, rising private and public investment in life sciences research, and diagnostics advancements in disease treatment. In addition, growing demand for new products and advanced technologies, along with rise in personalized medicine, targeted therapies, and genomics is expected to boost the growth of oligonucleotide synthesis market over the forecast period.

Latin America, and the Middle East and Africa regions accounted for smaller shares in the global oligonucleotide synthesis market in 2016. However, increasing government initiatives undertaken by governments to attract major players, and encourage research and innovations in Latin America, and Middle East & Africa regions, is expected to drive the growth of the oligonucleotide synthesis market in the regions during 2017-2025.

Major players in the global Oligonucleotide synthesis market include Thermo Fisher Scientific, Sigma-Aldrich Corporation (a part of Merck KGaA), Integrated DNA Technologies, GE Healthcare, Kaneka Eurogentec S.A., Agilent Technologies, BioAutomation, Eurofins Genomics, GeneDesign, Inc., among others.

Read Report - http://www.transparencymarketresearch.com/oligonucleotide-synthesis-market.html